S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
CNSX:HUGE

FSD Pharma (HUGE) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,870 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsInsider TradesHeadlines

HUGE stock logo

About FSD Pharma (CNSX:HUGE) Stock

FSD Pharma Inc. operates as a cannabis company in Canada. It is involved in hydroponic indoor cannabis production and processing activities. The company, through its subsidiary, FV Pharma Inc., holds license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations. It has a strategic alliance agreement with SciCann Therapeutics Inc. for the production and distribution of cannabinoid-based, patent pending, and indication-specific products developed by SciCann Therapeutics Inc. The company was formerly known as Century Financial Capital Group Inc. and changed its name to FSD Pharma Inc. in May 2018. FSD Pharma Inc. was incorporated in 1994 and is headquartered in Cobourg, Canada.

Receive HUGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter.

HUGE Stock News Headlines

May 25, 2023 | finance.yahoo.com
FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
May 13, 2023 | finance.yahoo.com
FSD Pharma Inc. (HUGE.CN)
June 3, 2023 | Behind the Markets (Ad)
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
May 11, 2023 | finance.yahoo.com
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
May 10, 2023 | msn.com
Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed
May 10, 2023 | finance.yahoo.com
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
April 19, 2023 | benzinga.com
Dynamic Duo of Celsius Holdings Fame join FSD Pharma calling Medical Product under Development "Unique and Disruptive"
April 19, 2023 | americanbankingnews.com
Zeeshan Saeed Purchases 23,000 Shares of FSD Pharma Inc (CNSX:HUGE) Stock
June 3, 2023 | Behind the Markets (Ad)
The 4th Military Revolution is Happening
. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>
April 12, 2023 | finance.yahoo.com
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023
April 12, 2023 | finance.yahoo.com
IIROC Trading Halt - HUGE
April 12, 2023 | finance.yahoo.com
IIROC Trade Resumption - HUGE
February 21, 2023 | finance.yahoo.com
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum
February 15, 2023 | finance.yahoo.com
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
February 7, 2023 | proactiveinvestors.com
FSD Pharma receives regulatory clearance for proposed Phase 1 clinical trial of multiple sclerosis drug candidate Lucid-MS
January 17, 2023 | proactiveinvestors.com
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS
January 17, 2023 | finance.yahoo.com
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
January 9, 2023 | msn.com
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
January 9, 2023 | proactiveinvestors.com
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
January 9, 2023 | financialpost.com
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
January 6, 2023 | finance.yahoo.com
FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023
September 6, 2022 | finance.yahoo.com
FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome
June 1, 2022 | proactiveinvestors.com
FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
May 6, 2022 | finance.yahoo.com
FSD Pharma Announces Dismissal of Derivative Complaint
May 2, 2022 | seekingalpha.com
FSD Pharma engages Tekkfund to help with business development strategies
April 21, 2022 | proactiveinvestors.com.au
FSD Pharma adds two new faces to its advisory board
April 21, 2022 | finance.yahoo.com
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board
See More Headlines


Industry, Sector and Symbol

Stock Exchange
CNSX
Industry
Software - Application
Sub-Industry
N/A
Sector
Computer and Technology
Current Symbol
CNSX:HUGE
CUSIP
N/A
CIK
N/A
Web
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A














HUGE Stock - Frequently Asked Questions

What other stocks do shareholders of FSD Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Canopy Growth (WEED), Aurora Cannabis (ACB), Cannara Biotech (LOVE), Aphria (APHA), Bombardier, Inc. Class B (BBD.B), Costco Wholesale (COST) and Enbridge (ENB).

What is FSD Pharma's stock symbol?

FSD Pharma trades on the CNSX under the ticker symbol "HUGE."

How do I buy shares of FSD Pharma?

Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (CNSX:HUGE) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -